Financial Report: Genzyme 1Q

Genzyme 1Q

1Q Revenues: $1.1 billion (+4%)

1Q Earnings: $195.5 million (+35%)

Comments: Myozyme sales were flat at $67.4 million. In February, the company received EU approval of Myozyme produced at the 4000 L scale. Fabrazyme sales were $122.2 million (+5%). Cerezyme sales were $296.0 million (-3%). Sales of Aldurazyme were flat at $36.8 million. Renvela and Renagel sales were $170.6 million (+1). Sales of Thyrogen were up 15% to $38.8 million. Revenue from the company’s Hematologic Oncology segment was $35.9 million (+50%), driven by the launch of Mozobil and an increase in U.S. sales of Clolar.